HM781-36B

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited, Yonsei University

Conditions

Advanced Solid TumorHNSCC

Phase 1

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

CompletedNCT01455571

Hanmi Pharmaceutical Company LimitedAdvanced Solid Tumor

Start: 2009-11-30End: 2013-01-31Updated: 2014-02-26

Phase 2

Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy

Yonsei UniversityHNSCC

Start: 2014-08-31End: 2019-07-31Target: 49Updated: 2019-03-18

Related Papers

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Cancer Medicine2021-09-1611 citations